- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01062204
Altrazeal™ Versus Aquacel® Ag for Partial Thickness Skin Donor Sites
February 3, 2010 updated by: ULURU Inc.
A Randomized Comparison Study of a Flexible HydrogelNanoparticle Wound Dressing (Altrazeal) Versus a Sodium Carboxymethylcellulose Dressing (Aquacel Ag) as Dressings for Partial Thickness Skin Graft Donor Sites
The primary objective of the study is to evaluate the time to wound healing in skin graft donor sites with a new treatment (Altrazeal dressing) compared to standard of care treatment (Aquacel Ag- Carboxymethylcellulose dressing) in partial thickness skin graft donor sites.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a single center, randomized, therapeutic exploratory study to monitor wound healing with the new AltrazealTM flexible hydrogel nanoparticle dressing compared to the existing treatment standard (Aquacel ® AG sodium carboxymethylcellulose dressing) in patients with at least two skin graft donor sites.
40 patients with at least 2 skin graft donor sites, ranging in age from 3 and 85 years, will be enrolled.
Children (age 3 to 16 inclusive) will be included in the patient population if possible, but should not exceed 50% of all patient enrolled.
Researchers will first identify the skin donor sites (A and B) for each patient and take baseline digital images and measurements immediately following surgery (Day 1).
Trained personnel will apply the dressings provided by the Sponsor for and labeled as A or B by the Sponsor in a random fashion.
Typical meticulous wound care and adequate analgesic medical coverage will be provided for the duration of the study.
Both the patient and medical staff will be trained on instructions for use of each dressing.
The patients will be monitored daily as part of standard procedure while they are in the in-patient setting.
If and when patients move to the out-patient setting, they will continue to be monitored at least every-other-day at the study center.
On each day (in-patient) or every-other-day (outpatient), the physician will determine whether each skin graft donor site has healed per standard care guidelines (i.e.
> 95% re-epithelization), and pain and adverse events will be monitored.
The last study visit will be on Day 24 or on the day when both wounds have been assessed as "healed", whichever comes first.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390-9158
- University of Texas Southwestern Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 85 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patient is between the ages of 3 and 85 Note: In order to maintain a broad representation of ages, no more than 50% of the patients enrolled in the study should be between the ages of 3 and 16, inclusive.
- Patient is in general good health
- Patient has two independent skin donor sites of approximately the same dimensions.
- Patient is willing and able to cooperate with the protocol for duration of study.
- Patient is capable of providing informed consent and HIPAA authorization
- Ability to read and speak either English or Spanish
Exclusion Criteria:
- Male or female patient is less than 3 years of age or more than 85 years of age
- Patient has acutely infected wounds
- Patient has wounds with surrounding cellulites
- Patient has a history of hypersensitivity to any components of either the nanoparticle or sodium carboxymethylcellulose dressing, or any known sensitivities to other hydrogel bandage treatments
- Patient has a concurrent clinical condition, which in the judgment of the Investigator could either pose a health risk to the patient while participating in this study, or could potentially influence the outcome of the study;
- Patient has history of poor wound healing or any skin/immune system condition that would increase likelihood of wound irritation, infection or increase chance of early termination
- Patient is unable to communicate or to cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to wound healing (re-epithelialization), in days assessed by the physician according to the study center's Standard of Care, for each wound dressing.
Time Frame: 24 days
|
24 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient's comfort
Time Frame: 24 days
|
24 days
|
Patient's pain
Time Frame: 24 days
|
24 days
|
Infections
Time Frame: 24 days
|
24 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Primary Completion (Actual)
December 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
February 2, 2010
First Submitted That Met QC Criteria
February 3, 2010
First Posted (Estimate)
February 4, 2010
Study Record Updates
Last Update Posted (Estimate)
February 4, 2010
Last Update Submitted That Met QC Criteria
February 3, 2010
Last Verified
February 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UC-6U1102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Partial-thickness Skin Donor Sites
-
Brigham and Women's HospitalMedline IndustriesCompletedSplit-thickness Skin Graft Donor Sites
-
ConvaTec Inc.Bristol-Myers SquibbCompletedSplit-Thickness Donor Sites.United States
-
Lee's Pharmaceutical LimitedGuangzhou First People's Hospital; Ruijin HospitalCompletedSplit-thickness Skin Graft Donor Sites
-
Brigham and Women's HospitalWithdrawnBurns | Split-thickness Skin Graft Donor Sites
-
University of Mississippi Medical CenterWithdrawnSplit-thickness Skin Graft Donor SitesUnited States
-
Klinik BogenhausenCompletedReepithelialization of Skin Graft Donor SitesGermany
-
Edixomed LtdTerminatedNitric Oxide Generating Gel Dressing in Patients With Superficial Partial Thickness Wounds (ProNOx2)Superficial Partial Thickness Burn | Skin Graft; ComplicationsUnited Kingdom
-
Smith & Nephew, Inc.CompletedPartial Thickness Supraspinatus Tendon Tear | Full Thickness Supraspinatus Tendon TearUnited States
-
Melva LouisaTerminated
-
Amarantus BioScience Holdings, Inc.Amarex Clinical ResearchUnknownThermal Injury | Deep Partial-Thickness Burn | Full-Thickness BurnUnited States
Clinical Trials on Altrazeal
-
ULURU Inc.Navy Advanced Medical Development (NAMD) CommandActive, not recruitingWounds and InjuriesUnited States
-
ULURU Inc.Naval Medical Research Center; Military Technology Enterprise Consortium (US)RecruitingDiabetic Foot UlcerUnited States
-
ULURU Inc.United States Department of DefenseRecruitingPressure Ulcers Stage II | Pressure Ulcers Stage III | Pressure Ulcer, Stage IVUnited States
-
ULURU Inc.Terminated